Eli Lilly has unveiled promising new data for its GLP-1 pill, signaling a potential breakthrough in treating type 2 diabetes. Released on April 17, 2025, by Good Morning America, the data reveals that the oral medication could significantly enhance blood sugar control and aid in weight management. GLP-1, or glucagon-like peptide-1, is an emerging treatment option that mimics natural hormones to regulate blood glucose levels. This development positions Eli Lilly at the forefront of diabetes care innovation, offering an effective and convenient alternative to traditional injections. The study’s findings suggest that with further research and clinical trials, Eli Lilly’s GLP-1 pill could transform diabetes management for millions. With diabetes cases rising globally, this breakthrough underscores the pill’s potential impact on public health, making it a noteworthy advance in the field of endocrinology.
Good Morning AmericaNew data shows cost of living pressures impacting charities and communities
June 11, 2026
Recent data from the Australian Charities and Not-for-profits Commission (ACNC) reveals that rising cost of living pressures are significantly impacting charities and communities across Australia.